Extended Hormone Therapy Doesn’t Help Some Prostate Cancer Patients: Study

Fewer Weeks of Hormone Therapy Before Radiation Reduces Side Effects, Yields Comparable Disease-Specific-Survival in Intermediate Risk Prostate Cancer

Disease-specific survival was 96 percent in both groups. The study was scheduled for presentation Monday at the annual meeting of the American Society for Radiation Oncology, in Atlanta. “Most clinicians have felt that ‘more was better’ when it came to blocking testosterone in prostate cancer patients, however, results for the specific endpoints we focused on, OS [overall survival] and DSS [disease-specific survival], indicate that this was clearly not the case,” study lead author Dr. Amin Mirhadi, a radiation oncologist at Cedars-Sinai Medical Center in Los Angeles, said in a society news release. “This data supports administering less treatment, which will result in fewer side effects and reduce patients’ overall health care costs,” Mirhadi added.
For the original version including any supplementary images or video, visit http://www.newsday.com/news/health/extended-hormone-therapy-doesn-t-help-some-prostate-cancer-patients-study-1.6124649

However, estrogen alone can increase your risk of developing uterine cancer . Many studies have looked at the association between hormone replacement therapy and breast cancer . The best evidence for the benefits and risks of hormone replacement therapy come from the Women’s Health Initiative (WHI), a large study involving more than 16,000 healthy women. The results published in July 2002 showed the risks of combined HRT with estrogen plus progestin outweigh the benefits.
For the original version including any supplementary images or video, visit http://www.webmd.com/breast-cancer/guide/breast-cancer-hormone-replacement-therapy-cancer-risk

Hormone Replacement Therapy and Breast Cancer Risk

ET, Georgia World Congress Center 1Radiation Therapy Oncology Group 9910: Phase III Trial to Evaluate the Duration of Neoadjuvant (NEO) Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer (PCa) T. M. Pisansky1, D. Hunt2, L. G. Gomella3, M. B.
For the original version including any supplementary images or video, visit http://markets.financialcontent.com/stocks/news/read/25183429/Fewer_Weeks_of_Hormone_Therapy_Before_Radiation_Reduces_Side_Effects


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s